All In Biotech

Drug Trial Radar · NCT06787144

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

A Phase 1 Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Jan 23, 2025

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
Enliven TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.

Conditions

  • CML (Chronic Myelogenous Leukemia)
  • Chronic Phase CML

Interventions

  • ELVN-001Drug

    Orally once or twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence of dose limiting toxicitiesTime frame: 28 days
  2. Part 1: Incidence of adverse events (AEs)Time frame: Up to 28 days
  3. Part 1: Incidence of clinically significant laboratory abnormalitiesTime frame: Up to 28 days
  4. Part 1: Incidence of clinically significant ECG abnormalitiesTime frame: Up to 28 days
  5. Part 2: Incidence of adverse eventsTime frame: Up to 3 years
  6. Part 2: Incidence of clinically significant laboratory abnormalitiesTime frame: Up to 3 years
  7. Part 2: Incidence of clinically significant ECG abnormalitiesTime frame: Up to 3 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Akita University Hospital

    Akita, Akita, Japan · Recruiting

  • Aiiku Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • The University of Osaka Hospital

    Suita-shi, Osaka, Japan · Recruiting

  • Tokyo Medical University Hospital

    Shinjuku-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.